AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 62 min read$AVR

L1 Capital Pty Ltd sold $4.1M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 495,189 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.30 ($8.23–$8.30, $4.11M total) across 2 trades over 2026-08-04 to 2026-08-05.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Aug 6, 2026, 10:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A large-holder open-market sale can affect sentiment, but without accompanying company news in the text, it is more likely to be a positioning signal than a fundamental reset.

02

Market read

Traders may monitor for follow-on selling or interpret the sale as a sentiment headwind, but the article does not provide new operational or financial information.

03

What to watch

Because the transaction is indirect and the filing lacks stated rationale, traders may over-weight it versus other upcoming catalysts (earnings, trial updates, financing).

Relevance 6/10Novelty 4/10Timing: filed 2026-08-06, covering sales on 2026-08-04 to 2026-08-05

Background

This is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp (AVR), reported by L1 Capital Pty Ltd as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 495,189 shares of Anteris Technologies Global Corp (AVR) for about $4.11M via open-market trades.

Expected impact

Near-term impact is likely limited, with focus on whether further selling continues or if the sale is routine under a 10b5-1 plan (here, none is stated).

Evidence & confidence

Form 4 provides transaction details and size, but the article does not include earnings, contracts, regulatory actions, or other company-specific catalysts that would reprice the stock.

Market effects

Sector

No sector-level implications are provided; this is a single-issuer Form 4 transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be non-informational (liquidity, diversification, tax, or planned disposition), especially since the filing does not state a 10b5-1 plan but still reflects a discrete, dated window.

Key entities

  • issuer
    Anteris Technologies Global Corp

    Company whose shares were sold; ticker AVR.

  • 10% owner
    L1 Capital Pty Ltd

    Reporter of the Form 4 transaction, selling shares via indirect holdings.

  • regulatory filing
    SEC Form 4

    Primary-source disclosure of insider transaction details.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVR insider trading history →

Related articles

NOV 1
$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

finance.yahoo.com2 min
NOV 1
$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

mykxlg.com2 min
OCT 20
$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.

finance.yahoo.com2 min